GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ikena Oncology Inc (NAS:IKNA) » Definitions » Equity-to-Asset

Ikena Oncology (Ikena Oncology) Equity-to-Asset : 0.90 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ikena Oncology Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Ikena Oncology's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $155.35 Mil. Ikena Oncology's Total Assets for the quarter that ended in Mar. 2024 was $172.78 Mil.

The historical rank and industry rank for Ikena Oncology's Equity-to-Asset or its related term are showing as below:

IKNA' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.72   Med: 0.83   Max: 0.91
Current: 0.9

During the past 5 years, the highest Equity to Asset Ratio of Ikena Oncology was 0.91. The lowest was -0.72. And the median was 0.83.

IKNA's Equity-to-Asset is ranked better than
84.98% of 1558 companies
in the Biotechnology industry
Industry Median: 0.67 vs IKNA: 0.90

Ikena Oncology Equity-to-Asset Historical Data

The historical data trend for Ikena Oncology's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ikena Oncology Equity-to-Asset Chart

Ikena Oncology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
-0.72 -0.60 0.84 0.85 0.88

Ikena Oncology Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.89 0.91 0.72 0.88 0.90

Competitive Comparison of Ikena Oncology's Equity-to-Asset

For the Biotechnology subindustry, Ikena Oncology's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ikena Oncology's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ikena Oncology's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Ikena Oncology's Equity-to-Asset falls into.



Ikena Oncology Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Ikena Oncology's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=169.757/192.092
=0.88

Ikena Oncology's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=155.347/172.782
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ikena Oncology  (NAS:IKNA) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Ikena Oncology Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Ikena Oncology's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Ikena Oncology (Ikena Oncology) Business Description

Traded in Other Exchanges
N/A
Address
645 Summer Street, Suite 101, Boston, MA, USA, 02210
Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. its other product candidates are IK-175 and IK-595.
Executives
Owen Hughes director C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Jotin Marango officer: CFO & Head of Corp. Dev. C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Francisco Oliveira officer: Principal Accounting Officer IKENA ONCOLOGY, INC., 645 SUMMER STREET, SUITE 101, BOSTON MA 02210
Richard Wooster director C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Xiaoyan Michelle Zhang officer: Chief Scientific Officer C/O IKENA ONCOLOGY, INC., 645 SUMMER STREET SUITE 101, BOSTON MA 02210
Jean Francois Formela director C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451
Atlas Venture Fund Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Maria Koehler director C/O REPARE THERAPEUTICS INC., 7210 FREDERICK-BANTING, SUITE 100, ST-LAURENT A8 H4S 2A1
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
David P Bonita director C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Mark Manfredi director, officer: President & CEO C/O IKENA ONCOLOGY, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Maude Tessier officer: Chief Business Officer C/O IKENA ONCOLOGY, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Jeffrey Ecsedy officer: Chief Scientific Officer C/O IKENA ONCOLOGY, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Atlas Venture Associates Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Xi, Llc 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139

Ikena Oncology (Ikena Oncology) Headlines